AdrianoPirisMD

Pathology • Needham, MA

Dermatopathology, Anatomic Pathology, Clinical Pathology

Instructor in Pathology, Massachusetts General Hospital

Join to view full profile

Dr. Piris is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Piris' full profile

Already have an account?

Office
15 Crawford St
Ste 100
Needham, MA 02494
Phone+1 617-969-4100

Education & Training

Beth Israel Deaconess Medical Center/Harvard Medical SchoolFellowship, Dermatopathology, 2006 - 2007
Massachusetts General HospitalResidency, Pathology-Anatomic and Clinical, 1998 - 2000
Universidad Nacional de Asuncion Faculty of MedicineClass of 1993

Certifications & Licensure

RI State Medical License 2020 - 2026
MA State Medical License 2006 - 2025
FL State Medical License 2017 - 2022
OH State Medical License 2017 - 2022
VA State Medical License 2018 - 2020
NH State Medical License 2017 - 2019
NJ State Medical License 2017 - 2019
NY State Medical License 2017 - 2019
WV State Medical License 2017 - 2019
CT State Medical License 2017 - 2018
DC State Medical License 2018 - 2018
PA State Medical License 2017 - 2018
American Board of Pathology Pathology - Anatomic
American Board of Pathology Dermatopathology
Join now to see all

Publications & Presentations

PubMed

59 citations
Increased diagnosis of thin superficial spreading melanomas: A 20-year study
Jason E. Frangos, Lyn M. Duncan, Adriano Piris, Rosalynn M. Nazarian, Martin C. Mihm
Journal of the American Academy of Dermatology. 2012-09-01
734 citations
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma
Dennie T. Frederick, Adriano Piris, Alexandria P. Cogdill, Zachary A. Cooper, Cecilia Lezcano
Clinical Cancer Research. 2013-03-01
117 citations
TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma
Ryan B. Corcoran, Stephen M. Rothenberg, Aaron N. Hata, Anthony C. Faber, Adriano Piris
Science Translational Medicine. 2013-07-31

Lectures

Melanoma and Mimics: New Diagnostic and Treatment Modalities
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/3/2019

Press Mentions

Large-Scale Screen of Drug Combinations Identifies Potential Treatment for Resistant, BRAF-Mutant MelanomaOctober 26th, 2015